title: Excision repair cross complementing 3 expression is involved in patient prognosis and tumor progression in esophageal cancer.
abstract: The prognosis of patients with esophageal cancer remains poor. TNM classification is not sufficient to predict the prognosis. Therefore, novel predictive markers of the prognosis of esophageal cancer patients are awaited. The abnormality of the nucleotide excision repair (NER) is often involved in human cancers. Excision repair cross complementing 3 (ERCC3) contributes to NER. In esophageal cancer, ERCC3 expression has not been studied. Expression of ERCC3 was quantified by real-time reverse transcription polymerase chain reaction (RT-PCR) using LightCycler in 43 primary esophageal squamous cell carcinomas (ESCCs) and their paired normal esophageal mucosa. We examined the correlation between the ERCC3 expression and the clinicopathological factors and prognosis of ESCC patients. ERCC3 expression level was significantly correlated with the pathologic stage, tumor size and local invasiveness (t-factor) in esophageal cancer tissues. Reduced expression of ERCC3 was accompanied with tumor progression (p=0.0049) and higher pathologic stage (p=0.020). Moreover, ESCC patients with low ERCC3 mRNA expression had significantly shorter post-operative survival time than those with high expression (p=0.0003). In esophageal cancer, reduced expression of ERCC3 was correlated with local tumor progression and poor prognosis after operation.
authors.affiliation: Second Department of Surgery, Nagoya City University Medical School, Nagoya 467-8601, Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Terashita
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishiguro
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Haruki
authors.forename: Hironori
authors.initials: H
authors.lastname: Sugiura
authors.forename: Tadashi
authors.initials: T
authors.lastname: Tanaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kimura
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Shinoda
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kuwabara
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Fujii
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D004265:DNA Helicases / Q000235:genetics* / Q000378:metabolism; D004260:DNA Repair; D004268:DNA-Binding Proteins; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D004947:Esophagus / Q000378:metabolism; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D011379:Prognosis; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C072022:XPBC-ERCC-3 protein; D004265:DNA Helicases